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Abstract
Aim To evaluate the long-term safety and efficacy of
prolonged-release oxycodone/naloxone (OXN PR) and its
impact on quality of life (QoL), in patients with moderate-
to-severe cancer pain.
Methods This was an open-label extension (OLE) of a 4week,
randomized, double-blind (DB) study in which patients with
moderate-to-severe cancer pain had been randomized to OXN
PR or oxycodone PR (OxyPR). During the OLE phase, pa-
tients were treated with OXN PR capsules (≤20/60 mg/day)
for ≤24 weeks. Outcome measures included safety, efficacy
and QoL.
Results One hundred and twenty-eight patients entered the
OLE, average pain scores based on the modified Brief Pain
Inventory—Short Form were low and stable over the 24-week
period. The improvement in bowel function and constipation
symptoms as measured by the Bowel Function Index and
patient assessment of constipation in patients treated with
OXN PR during the 4-week DB study was maintained. In
patients treated with OxyPR during the DB phase, bowel
function and constipation symptoms were improved during
the OLE. In the DB and in the OLE, health status and QoL
were similar for patients treated with OXN PR and OxyPR.
There were no unexpected safety or tolerability issues.
Conclusions In patients with moderate-to-severe cancer pain,
long-term use of OXN PR is well tolerated and effective,
resulting in sustained analgesia, improved bowel function
and improved symptoms of constipation.
Keywords Oxycodone . Naloxone . Opioid-induced
constipation . Analgesia . Bowel function
Introduction
Pain is a common and debilitating symptom of cancer and can
significantly impact the lives of patients through detrimental
effects on physical functioning, psychological well-being and
social interactions [1]. Pain affects a large proportion of cancer
patients, with prevalence rates ranging from 33 % in patients
after curative treatment to 64 % in patients with advanced,
metastatic or terminal phase disease [2, 3]. In a 2009 European
survey, 56 % of cancer patients were demonstrated to suffer
pain several times per month, with over 90 % of these
reporting their pain as moderate to severe in intensity [4].
Opioid analgesics are the established treatment for the
relief of moderate-to-severe cancer pain and several different
opioids are now available [5, 6]. For years, morphine has been
the accepted gold standard for the treatment of cancer pain and
is endorsed by the European Association of Palliative Care
[6]. Oxycodone (a semi-synthetic opioid analgesic) has prov-
en efficacy in the management of severe pain of different
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aetiologies [7–10]. A series of systematic reviews on the use
of opioids in cancer patients found that oxycodone and
hydromorphone have efficacy and tolerability profiles com-
parable with that of morphine [11, 12].
Although opioids have proven analgesic efficacy, their use is
frequently complicated by a range of side effects, which include
nausea, sedation, euphoria/dysphoria, constipation and itching
[13, 14]. The most common and often most debilitating side
effect is opioid-induced bowel dysfunction (OIBD), which
comprises a constellation of gastrointestinal (GI) adverse events
(AEs) including constipation, hard dry stools, straining, incom-
plete evacuation, bloating, abdominal cramping, abdominal
distension and increased gastric reflux [13, 15]. The primary
symptom of OIBD is constipation, which occurs in approxi-
mately 90 % of cancer patients receiving opioid therapy and
persists over time [14, 16, 17]. Current strategies to manage
OIBD are non-specific and frequently ineffective [18].
Increasing dietary fibre, fluid intake and physical mobility are
usually insufficient to prevent or treat OIBD and the majority of
patients receiving long-term opioid therapy require laxatives
[13]. Laxatives do not address the underlying opioid receptor-
mediated cause of constipation and evidence for their effective-
ness is weak; therefore, OIC persists in many patients [13, 19].
A novel therapeutic approach to bypass the GI effects of
opioids involves co-administration of an opioid antagonist (nal-
oxone). When administered orally in a prolonged-release (PR)
formulation, naloxone has a low systemic bioavailability
(<3 %) and antagonises peripheral opioid receptors in the GI
tract with little impact on centrally-acting opioid analgesia
[20–22]. Oral naloxone can, therefore, improve OIC [23, 24].
In patients with moderate-to-severe non-cancer pain, random-
ized phase III trials have demonstrated that co-administration of
prolonged-release (PR) oxycodone with naloxone (OXN PR)
provides effective analgesia whilst significantly reducing the
impact of OIBD and OIC compared with oxycodone PR alone
(OxyPR) [25–27] and that this effect is maintained over the
long term (≤52 weeks) [28]. Similar safety and efficacy has
been demonstrated in a randomized phase II study of OxyPR vs
OXN PR in patients with moderate-to-severe cancer pain [29];
although, the long-term effects on this patient population has
not yet been demonstrated. Here, we report results of a long-
term open-label extension (OLE) of the phase II study in which
patients were maintained on or switched to OXN PR.
Methods
Study design
This was a 24 week, uncontrolled, open-label extension of a
4 week, randomized, double-blind study (OXN2001S;
NCT00513656) [29] conducted to evaluate the long-term
safety and efficacy of OXN PR vs OxyPR in patients with
moderate-to-severe cancer pain. The study was performed in
compliance with good clinical practice and in accordance with
the Declaration of Helsinki.
Inclusion and exclusion criteria
Patients completing the double-blind period and those who
had discontinued prematurely due to constipation were eligi-
ble to enter the OLE phase. Patients aged ≥18 years were
enrolled into the double-blind phase of the study if they had
moderate-to-severe chronic cancer pain that required ‘round-
the-clock’ opioid therapy and constipation secondary to opi-
oid therapy [29].
Study treatment
During the double-blind phase, participants were randomized
to OXN PR or OxyPR for 4 weeks (≤120 mg/day). During the
OLE, all patients receivedOXNPR every 12 h for ≤24weeks).
Study Visit 9a (Day 1) was the first visit of the OLE phase of
the study and typically occurred on the same day as Visit 9
(end of the double-blind phase) (Figure 1A).
The initial starting dose was the effective analgesic dose
based on oxycodone or OXN PR that the patient was on at the
end of the double-blind phase. Any patient on a dose of
≤80 mg/day OxyPR was switched directly to OXN PR. For
example, all patients on 80mg/day OxyPR started with a daily
dose of OXN PR 80/40 mg. Those patients on >80 mg/day
OxyPR were switched to OXN PR in a stepwise manner. All
patients receiving 90, 100, 110, or 120 mg/day OxyPR were
started on OXN PR 40/20 mg 12 hourly with the remainder of
their oxycodone dose given as OxyPR. Dose titration was
permitted at the discretion of the investigator to ≤120/60 mg/
day. A total of 19 patients received OXN PR at a daily dose of
>80/40 mg; safety findings for these patients were no different
from the whole population.
Rescue medications (Oxy IR 5 mg and laxative bisacodyl
5 mg) were supplied for the first 7 days of the study. After
7 days, laxative use was documented as concomitant
medication.
Study assessments
Efficacy was evaluated based on the following measurements:
Brief Pain Inventory—Short Form (BPI-SF), a patient-rated
scale based on ‘least’, ‘average’ and ‘worst’ pain felt over the
previous week [30]; Bowel Function Index (BFI) a comprising
three components (ease of defecation, feeling of incomplete
bowel evacuations and personal judgement of constipation)
[31, 32]; patient assessment of constipation (PAC-SYM) [33];
rescue medications (Oxy IR and laxative); number of bowel
movements; health status (EuroQol EQ-5D) and quality of life
(QoL) (European Organisation for Research and Treatment of
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Cancer Quality of Life Questionnaire-Core 30; EORTCQLQ-
C30) [34, 35]. Safety assessments included adverse events
(AEs) and serious AEs, physical and laboratory evaluations,
12-lead electrocardiograph, and evaluation of the symptoms
of opiate withdrawal as measured by the Subjective Opiate
Withdrawal Scale (SOWS) collected 1 day and 1 week fol-
lowing the start of the OLE [36].
aCopyright for the BFI is owned by Mundipharma
Laboratories GmbH, Switzerland, 2002; the BFI is subject of
European Patent Application Publication No. EP 1,860,988 and
corresponding patents and applications in other countries.
Statistical analysis
All analyses were performed on the OLE safety population
(patients who received at least one dose of study medication
during the OLE. All efficacy and safety variables were sum-
marized descriptively. All continuous variables were summa-
rized using the following descriptive statistics: n, mean, stan-
dard deviation (SD), median, minimum and maximum. The




A total of 128 patients entered the OLE phase of which 126
(98.4 %) had previously completed the double-blind phase
and 2 (1.6 %) had discontinued due to constipation. All 128
patients in the OLE phase received study medication and 68
patients (53.1 %) completed the study. Fifty-three per cent and
56.9 % of patients were male and female, respectively, and the
mean age was 62.5 years. The most common cancers were
breast (19.5 %), lung (8.6 %) and prostate (11.7 %) (Table 1).
Efficacy
OXN PR dose
Mean duration of exposure to OXN PR was 122.2 days and
the mean daily dose was 56.2 mg. The majority of subjects
(69.5 %) remained on their starting dose for the duration of the












Lost to follow-up n=2











Fig 1 Study design (A) and
patient disposition (B). AEs
adverse events, n number of
patients; OLE open-label




randomization, V visit,WK week.
Superscript letter a indicates day
or week since the beginning of the
open-label extension phase; V9a
was the first visit of the open-label
extension phase and typically
occurred on the same day as visit
9 (end of double-blind phase).
Superscript letter b includes two
patients who discontinued from
the double-blind phase due to
constipation and entered the OLE
phase
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(usually 10 or 20 mg or higher) by the end of the study/
discontinuation.
Pain (BPI-SF)
At the end of the double-blind phase of the study in which
patients were treated with OxyPR or OXN PR, there was no
significant difference in pain control (as assessed by the BPI-
SF) between the two treatments [29]. At the beginning of the
OLE, BPI-SF pain scores for ‘average pain’ were low in both
groups: mean (SD) 3.42 (2.03) and 3.63 (1.76) for OXN PR
and OxyPR, respectively. BPI-SF scores remained consistent-
ly low and stable in both groups over the OLE period with
scores of 3.71 (2.12) for OxyPR and 3.56 (2.27) for OXN PR
at Week 24 (Figure 2).
Bowel function index
At the end of the double-blind phase, OXN PR is both statis-
tically significantly superior in respect to BFI and has also
demonstrated a change that is clinically relevant compared
with OxyPR [29]. For patients that received OXN PR during
the DB phase (OLE baseline score [SD]: 38.08 [26.94]), the
improvement in BFI was maintained during the OLE (mean
BFI: 37.90 [28.06] at Week 12 and 39.02 [27.70] at Week 24).
For patients treated with OxyPR during the DB phase (OLE
baseline score: 46.61 [26.84]), mean BFI scores were reduced
to 38.52 (27.69) at Week 12 and 38.78 (27.45) at Week 24,
comparable to those who had previously received OXN PR
(Figure 3).
Constipation symptoms (PAC-SYM)
At the end of the double-blind phase, a statistically signifi-
cantly greater improvement in constipation symptoms was
observed for OXN PR compared with OxyPR [29]. At the
beginning of the OLE phase, mean (SD) PAC-SYM total
symptoms scores were 10.55 (8.60) and 15.53 (10.20) for
OXN PR and OxyPR, respectively. The improvement in con-
stipation symptoms seen in the OXN PR group was main-
tained during the OLE, with a mean PAC-SYM (SD) of 12.14
(9.65) at Week 24. For patients who had received OxyPR
during the double-blind period, mean PAC-SYM scores were
reduced to 12.81 (10.10) at Week 24 (Table 2).
Rescue medication
During the first 7 days of the OLE, the need for rescue
medication was low. A total of 37.5 % of patients used
laxatives. The mean bisacodyl dose in 7 days was 6.09 mg,
which translates to approximately one tablet used in 7 days. A
mean of 1.1 (range: 0–3.9) capsules of Oxy IR 5 mg were
required for rescue analgesia per day.
QoL
In the double-blind phase of the study, health status and QoL
were similar between OXN PR and OxyPR groups [29].
Table 1 Patient demographics and clinical characteristics (safety
population)
Characteristic OXN PR (N=128)
Mean age, years (SD) 62.5 (10.3)
Age ≤65 years, n (%) 74 (57.8)





Mean (SD) 25.3 (5.1)
Median (range) 25.1 (16–40)
BMI body mass index, OXN PR prolonged-release oxycodone/naloxone
tablets, SD standard deviation
Fig 2 BPI-SF average pain scores (LOCF) by study visit (OLE safety
population). BPI-SF Brief Pain Inventory-Short Form, LOCF last obser-
vation carried forward, OLE open-label extension, OXN PR prolonged-
release oxycodone/naloxone tablets, OxyPR prolonged-release oxyco-
done tablets, SD standard deviation. Superscript letter a indicates day
or week since the beginning of the open-label extension phase. Data for
the DB period are based on the per protocol population (LOCF): OXN
PR, n=62 OxyPR, n=71; higher scores indicate more severe pain (0 no
pain, 10 most severe pain)
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These results were maintained during the OLE. In the total
OLE population, the mean (SD) EQ-5D index score was 0.49
(0.31) at day 1, 0.59 (0.25) at week 12 and 0.46 (0.38) at week
24. The EORTC QLQ-C30 global health status scores were
45.83 (20.36) at day 1, 53.08 (20.07) at week 12 and 43.06
(23.90) at week 24. For the specific EORTC constipation
scale, the score was at least maintained and suggested an
improvement over the OLE with mean (SD) scores in the total
OLE population of 45.31 (35.18) at day 1, 38.49 (35.66) at
week 12 and 42.71 (34.44) at week 24.
Safety
Overall, 93.8 % of patients experienced at least one AE in the
OLE phase of which 28.1 % were classed as having AEs
related to study treatment according to investigators. Fifty-
nine patients (46.1 %) experienced serious adverse events
(SAEs). A total of four SAEs in four patients were related to
study treatment: constipation, dyspnoea, paralytic ileus and
worsening of cancer-related pain. Two additional SAEs in one
patient were assessed as treatment-related by the sponsor. A
Fig 3 BFI scores (LOCF) by study visit (OLE safety population). BFI
bowel function index, LOCF last observation carried forward,OLE open-
label extension, OXN PR prolonged-release oxycodone/naloxone tablets,
OxyPR prolonged-release oxycodone tablets, SD standard deviation.
Superscript letter a indicates day or week since the beginning of the
open-label extension phase. Data for the DB period are based on the full
analysis population (LOCF); OXN PR, n=77; OxyPR, n=80; higher
scores indicate more severe constipation
Table 2 Patient assessment of
constipation using PAC-SYM
(OLE safety population)
Higher symptom scores and
higher frequency of symptoms
indicate more severe constipation
OLE open-label extension, PAC-
SYM Patient Assessment of Con-
stipation Symptoms, SD standard
deviation
Treatment during the DB phase All OLE patients (N=128)
OxyPR (n=62) OXN PR (n=66)
Total symptom score
Day 1
n 62 66 128
Mean (SD) 15.53 (10.20) 10.55 (8.60) 12.96 (9.70)
Week 12
n 41 43 84
Mean (SD) 13.22 (11.83) 9.67 (7.43) 11.40 (9.93)
Week 24
n 52 44 96
Mean (SD) 12.81 (10.10) 11.34 (9.14) 12.14 (9.65)
Frequency of symptoms
Day 1
n 61 66 127
Mean (SD) 1.93 (1.31) 1.44 (1.07) 1.68 (1.21)
Week 12
n 41 43 84
Mean (SD) 1.63 (1.39) 1.30 (1.06) 1.46 (1.24)
Week 24
n 51 43 94
Mean (SD) 1.67 (1.34) 1.77 (1.27) 1.71 (1.30)
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total of 38 patients discontinued during the OLE. In total, 28
patients (21.9 %) died during the study. Twenty-four of these
deaths were due to disease progression or events related to
disease progression; the other deaths were due to sepsis,
worsening dyspnoea, lung embolism and cardiac arrest. The
death fromworsening of dyspnoeawas recorded as unlikely to
be related to study medication. All other deaths were recorded
as unrelated to study medication. There were no clinically
important changes in vital signs, laboratory values and
electrocardiographs. Mean (SD) SOWS scores in the OLE
safety population were comparable with those collected in
the respective double-blind phase and decreased from 7.90
(7.39) at day 1 to 7.36 (6.24) at week 1 of the OLE. SOWS
scores were comparable in both patient groups of the double-
blind phase (Table 3).
Discussion
Pain is a common symptom of cancer, and if poorly
treated, can adversely affect patients’ physical func-
tioning, psychological well-being and social interac-
tions [4]. Whilst opioids are widely recommended to
relieve pain in cancer patients [6, 37], successful
management requires that the benefits of these agents
outweigh the impact of treatment-related side effects
[38]. Opioid-induced bowel dysfunction, particularly
OIC, is the most frequently reported AE experienced
by patients receiving long-term opioid therapy and
can be sufficiently severe to undermine the effective-
ness of pain management [13].
To our knowledge, this OLE study is the largest trial to date
evaluating OIC in cancer pain and provides a sound basis for
evaluation of long-term safety and efficacy data. Results from
this study demonstrate that long-term treatment (of at least
6 months) with OXNPR provides sustained analgesic efficacy
for patients with moderate-to-severe cancer pain whilst main-
taining improved bowel function. Increases in doses were
small and there were no withdrawals due to lack of therapeutic
effect indicating that pain control was maintained for the
duration of the study for most subjects. The average pain
scores based on the modified BPI-SF were low and stable
over the 24-week OLE, indicating good analgesic efficacy
during long-term treatment with OXN PR. The use of rescue
medication was low and did not lead to any concern over the
switching from OxyPR to OXN PR. The improvement in
bowel function demonstrated with OXN PR during the
double-blind phase of the study was maintained during the
24-week OLE phase, and patients who had received OxyPR
during the double-blind period experienced improvement in
bowel function following switch to OXN PR. Health status
and QoL appeared to be maintained over the course of the
OLE, with some possible improvements during the earlier part
of the study.
It should be noted that data for QoL at week 24 (visit 13)
included patients who had discontinued earlier in the study.
Week 12 (visit 12), however, included only those data record-
ed at the visit. This may have contributed to any observed
differences, particularly since the majority of discontinuations
were due to disease progression/worsening of the condition
and associated AEs.
The safety profile was as expected for this patient popula-
tion, in accordance with the safety profile of opioid analgesics
in this advanced cancer patient population. Although the
overall AE and discontinuation rates were high, this was not
unexpected considering the patient population and the dura-
tion of the study with respect to the course of cancer. The
Table 3 Summary of adverse events (OLE safety population)
Oxycodone/naloxone
Number of patients with
events, n (%)
(N=128)
Total AE 120 (93.8)
AEs related to study medication 36 (28.1)
Discontinuations due to AE 38 (29.7)
SAE 59 (46.1)
SAEs related to study medication 4 (3.1)
Blood and lymphatic system disorders 17 (13.3)
Anaemia 8 (6.3)
Gastrointestinal disorders 44 (34.4)













Increased blood uric acid 7 (5.5)
Increased gamma-glutamyl transferase 7 (5.5)
Decrease haemoglobin 15 (11.7)
Decreased lymphocyte count 10 (7.8)
Metabolism and nutrition disorders 26 (20.3)
Anorexia 11 (8.6)
Neoplasms benign, malignant and
unspecified (including cysts and polyps)
51 (39.8)
Cancer pain 22 (17.2)
Malignant neoplasm progression 32 (25.0)
AE adverse event, OLE open-label extension, SAE serious adverse event
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incidence of AEs in the OLE phase was comparable with that
in the double-blind phase. The most frequently reported AEs
were related to progression of underlying cancer disease, which
is reflected in the profile of the frequently reported AEs of
malignant neoplasm progression, cancer pain and nausea. The
rate of treatment-related AEs (28.1 %) in this cancer study was
in line with reported AEs in non-malignant pain populations in
OLE studies of OXN PR [28]. Although 59 patients (46.1 %)
experienced SAEs, the proportion considered related to study
treatment was low (only 4 patients; 3.1 %).
As with any clinical trial, the results of this study should be
interpreted with some consideration of its limitations. Open-
label extension studies are often uncontrolled and potentially
biased due to patient self-selection, and further, randomized
trials would better support the long-term use of OXN PR in
chronic cancer pain. However, open-label studies, allow for
greater patient exposure to medications, which enhances un-
derstanding of the efficacy and safety profile of the agent
being investigated over a longer time period. As such, these
results add to the accumulating evidence for the analgesic
efficacy and improvement in bowel function and QoL associ-
ated with OXN PR, and suggest that these effects can be
maintained during long-term therapy. Overall, the results re-
ported here provide further support for the findings from the 4-
week double-blind phase of this trial [29] and are also in line
with those seen in patients with non-malignant pain [25–28].
Conclusion
The findings presented here demonstrated that the benefits of
OXN PR seen in the double-blind study were maintained in
the 24-week OLE. For patients with moderate-to-severe can-
cer pain, this allows sustained analgesia whilst maintaining
improved bowel function and reduced symptoms of constipa-
tion. OXN PR was not associated with any unexpected safety
or tolerability issues. These findings may reassure clinicians
that patients may safely remain on stable drugs for pain as
their cancer progresses.
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